The study is being led by Principal Investigator Matthew Rizzo, MD, Faan, Fana, Professor Reynolds and Chair of the Department of Neurological Sciences at UNMC, Chief Physician of Nebraska Medicine’s Neurological Services and Chief Physician of Nebraska’s Clinical Neuroscience Programs. Medicine.
“We are very excited to have this important study underway,” said Dr. Rizzo.
The research team of Dr. Rizzo includes Jennifer Merickel, PhD, Cognitive Neuroscientist and Assistant Professor in the Department of Neurological Sciences at UNMC, and Brigette Soltis-Vaughan, an Advanced Practice Registered Nurse, Clinician and Researcher in the Department of Psychiatry at UNMC and Instructor in the Department of Neurological Sciences at UNMC.
“Enrolling the first patient in our second PTSD clinical trial is an important milestone for ANANDA’s clinical development program,” said sohail r. more, from ANANDA Chief Executive Officer.“We are delighted to partner with the UNMC research team in the evaluation of our promising drug for this very debilitating condition.”
This randomized, double-blind, placebo-controlled, phase II clinical trial plans to enroll 180 participants to provide rigorous evaluation of the efficacy and safety of NantheiaTM ATL5 .
ABOUT NANTHEIATM ATL5
NantheiaTM ATL5 is an investigational drug that uses cannabidiol in ANANDA’s proprietary Liquid Structure delivery technology. Preclinical and early clinical studies show that ANANDA’s Liquid StructureTM delivery technology (licensed by lyotropic delivery systems (lds) ltd in Jerusalem, Israel) enhances the efficacy and stability of cannabidiol. NantheiaTM ATL5 is an oral product with 100mg of cannabidiol per softgel.
ABOUT University of Nebraska Medical Center
As Nebraska’s only public academic health sciences center, UNMC is committed to educating a 21st century health workforce, to finding cures and treatments for devastating diseases, to providing the best care to patients, and serving the state and its communities through awards. winning publicity. unmc has six faculties, two institutes and a graduate program, serving more than 4,400 students in approximately 90 programs. UNMC researchers conduct cutting-edge research in neurological sciences, oncology, infectious diseases and other important areas.
ABOUT SCIENTIFIC ANANDA
ANANDA is a leading research biopharmaceutical company, pioneering high caliber clinical studies evaluating therapeutic indications such as PTSD, radiculopathic pain, anxiety and opioid use disorder (Mt. Sinai and UCLA). The company employs patented delivery technology to produce highly bioavailable, water-soluble, shelf-stable cannabinoids and other plant-derived compounds and focuses on producing premium quality, effective pharmaceuticals. The company is expanding its research base through several sponsored research agreements with universities to diversify its clinical portfolio.
See the original version on businesswire.com: